How endemic countries can accelerate lymphatic filariasis elimination? An analytical review to identify strategic and programmatic interventions

Journal of Vector Borne Diseases

Volumn 48, Issue 1, 2011, Pages 1-6

  Lahariya, Chandrakant ^a   Tomar, Shailendra S ^a,b  

^a Write Health Society for Community Health Actions   (India)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Elimination; India; Lymphatic filariasis; Mass drug administration; Neglected tropical disease

Indexed keywords

DIETHYLCARBAMAZINE;

COMMUNITY PROGRAM; EDUCATION PROGRAM; ENDEMIC DISEASE; FUNDING; HEALTH CARE ACCESS; HEALTH PERSONNEL ATTITUDE; HUMAN; INFECTION CONTROL; INTERPERSONAL COMMUNICATION; LEADERSHIP; LYMPHATIC FILARIASIS; MASS IMMUNIZATION; MEDICAL EDUCATION; PATIENT COMPLIANCE; POLITICAL PARTICIPATION; PREVENTIVE MEDICINE; PROFESSIONAL KNOWLEDGE; REVIEW; STRATEGIC PLANNING; SUSTAINABLE DEVELOPMENT;

COMMUNICABLE DISEASE CONTROL; DIETHYLCARBAMAZINE; ELEPHANTIASIS, FILARIAL; ENDEMIC DISEASES; HEALTH EDUCATION; HEALTH PERSONNEL; HUMANS;

EID: 79952964079     PISSN: 09729062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Recommendations of the International Task Force for Disease Eradication. MMWR Reco & Rep 1993; 42: 1-38.
2. World Health Report 1995: bridging the gaps. World Health Forum 1995; 16: 377-85.
3. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 1997; 75: 491-503.
4. Global program to eliminate lymphatic filariasis: progress report on mass drug administration in 2008. WHO Wkly Epidemiol Rep 2009; 84: 437-44.
5. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2008; 2: e317.
6. Savioli LCD, Ottesen EA, Montresor A, Hayashi, Satyanarayana K. Intestinal worms beware: development in antihelminthic chemotherapy usage. Parasitol Today 1997; 13: 43-4.
7. Stephenson I, Wiselka M. Drug treatment of tropical parasitic infections: recent achievements and developments. Drugs 2000; 60: 985-95.
8. Ramaiah KD, Das PK, Appavoo NC, Ramu K, Augustin DJ, Kumar KN, et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual singledose DEC mass treatment and some related operational aspects. Trop Med Int Health 2000; 5: 842-7.
9. Babu BV, Behera DK, Kerketta AS, Mishra S, Rath K, Swain BK, et al. Use of an inclusive-partnership strategy in urban areas of Orissa, India, to increase compliance in a mass drug administration for the control of lymphatic filariasis. Ann Trop Med Parasitol 2006; 100: 621-30.
10. Ottesen EA, Vijayasekaran V, Kumaraswami V, Perumal Pillai SV, Sadanandam A, Frederick S, et al. A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis. N Engl J Med 1990; 322: 1113-7.
11. Houston R. Salt fortified with diethylcarbamazine (DEC) as an effective intervention for lymphatic filariasis, with lessons learned from salt iodization programmes. Parasitol 2000; 121: s161-73.
12. Remme JH, Alley ES, Plaisier AP. Estimation and prediction in tropical disease control: the example of onchocerciasis. In: Mollison D, editor. Epidemic models: their structure and relation to data. Cambridge, UK: Cambridge University Press 1995; 372-92.
13. Aswathy S, Beteena K, Leelamoni K. Mass drug administration against filariasis in India: perceptions and practices in a rural community in Kerala. Ann Trop Med Parasitol 2009; 103: 617-24.
14. Babu BV, Satyanarayana K. Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari district, south India. Trop Doct 2003; 33: 79-82.
15. Kerketta AS, Babu BV. Clinicians' attitude on mass drug administration under the program to eliminate lymphatic filariasis: a qualitative study from Orissa, India. Asia Pac J Public Health 2009; 21: 112-7.
16. Lammie P, Milner T, Houston R. Unfulfilled potential: using diethylcarbamazine-fortified salt to eliminate lymphatic filariasis. Bull World Health Organ 2007; 85: 545-9.
17. Hawking F, Marques RJ. Control of bancroftian filariasis by cooking salt medicated with diethylcarbamazine. Bull World Health Organ 1967; 37: 405-14.
18. Kanda T, Sasa M, Kato K, Kawai J. Pilot experiments on the mass treatment of bancroftian filariasis with medicated food or drink. Japanese J Experimental Med 1967; 37: 141-7.
19. Sen AB, Chandra R, Katiyar JC, Chandra S. Diethylcarbamazine medicated salt in the chemotherapeutic control of filariasis due to Wuchereria bancrofti in an open community. Indian J Med Res 1974; 62: 1181-9.
20. Rao CK, Rao PK, Das M, Rao NK. Control of bancroftian filariasis with diethylcarbamazine medicated salt in open communities in rural and urban areas. J Commun Dis 1976; 8: 193-202.
21. Reddy GS, Venkateswaralu N. Mass administration of DECmedicated salt for filariasis control in the endemic population of Karaikal, south India: implementation and impact assessment. Bull World Health Organ 1996; 74: 85-90.
22. Michael E, Meyrowitsch DW, Simonsen PE. Cost and cost-effectiveness of mass diethylcarbamazine chemotherapy for the control of bancroftian filariasis: comparison of four strategies in Tanzania. Trop Med Int Health 1996; 1: 414-26.
23. Noroes J, Addiss D, Amaral F, Coutinho A, Medeiros Z, Dreyer G. Occurrence of living adult Wuchereria bancrofti in the scrotal area of men with microfilaraemia. Trans R Soc Trop Med Hyg 1996; 90: 55-6.
24. Shenoy RK, Varghese J, Kuttikkal V. The efficacy, tolerability and safety of diethylcarbamazine-fortified salt in the treatment of the microfilaraemias of brugian flariasis: an open, hospitalbased study. Ann Trop Med Parasitol 1998; 92: 285-93.
25. Michael E, Malecela-Lazaro MN, Simonsen PE, Pedersen EM, Barker G, Kumar A, et al. Mathematical modelling and the control of lymphatic filariasis. Lancet Infect Dis 2004; 4: 223-34.
26. Stolk WA, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JD. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Infect Dis 2003; 188: 1371-81.
27. Esterre P, Vigneron E, Roux J. The history of lymphatic filariasis control programme in French Polynesia: lessons from a 50 years effort. Bull Soc Pathol Exot 2005; 98: 41-50.
28. Ichimori K. Entomology of the filariasis control program in Samoa: Aedes polynesiensis and Ae. samoanus. Med Entomol Zool 2001; 52: 11-21.
29. Mataika JU. Comparison of the efficacy of diethylcarbamazine between 5 rounds of annual single dose treatment and an intensive 28 dose-treatment spread over 2 years against diurnally subperiodic Wuchereria bancrofti in Fiji. Fiji Med J 1993; 19: 2-6.
30. Report of the ninth workshop for Pacific lymphatic filariasis program managers. Manila: WHO Western Pac Region 2008; p. 5-38.
31. Babu BV, Kar SK. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 2004; 9: 702-9.
32. Cantey PT, Rao G, Rout J, Fox LM. Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa state, India 2008. Trop Med Int Health 2010; 15: 224-31.
33. Nandha B, Sadanandane C, Jambulingam P, Das P. Delivery strategy of mass annual single dose DEC administration to eliminate lymphatic filariasis in the urban areas of Pondicherry, south India: 5 years of experience. Filaria J 2007; 6: 7.
34. Lahariya C, Mishra A. Strengthening of mass drug administration implementation is required to eliminate lymphatic filari asis from India: an evaluation study. J Vector Borne Dis 2008; 45: 313-20.
35. Talbot JT, Viall A, Direny A, de Rochars MB, Addiss D, Streit T, et al. Predictors of compliance in mass drug administration for the treatment and prevention of lymphatic filariasis in Leogane, Haiti. Am J Trop Med Hyg 2008; 78: 283-8.
36. Ramaiah KD, Vijay Kumar KN, Chandrakala AV, Augustin DJ, Appavoo NC, Das PK. Effectiveness of community and health services-organized drug delivery strategies for elimination of lymphatic filariasis in rural areas of Tamil Nadu, India. Trop Med Int Health 2001; 6: 1062-9.
37. Babu BV, Mishra S. Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Trans R Soc Trop Med Hyg 2008; 102: 1207-13.
38. Nandha B, Krishnamoorthy K. School-based health education campaign-a potential tool for social mobilization to promote the use of DEC-fortified salt towards elimination of lymphatic filariasis. Health Educ Res 2007; 22: 539-46.
39. Freeman AR, Lammie PJ, Houston R, LaPointe MD, Streit TG, Jooste PL, et al. A community-based trial for the control of lymphatic filariasis and iodine deficiency using salt fortified with diethylcarbamazine and iodine. Am J Trop Med Hyg 2001; 65: 865-71.
40. Shu EN, Onwujekwe EO, Lokili P, Okonkwo PO. A health club for a community school in south-eastern Nigeria: influence on adult perception of onchocerciasis and compliance with community-based ivermectin therapy. Trop Med Int Health 2000; 15: 222-6.
41. Nanda BS, Panicker KN. Student's community a potential force for filariasis control. Peoples Action 1991; 6: 9-11.
42. Mathieu E, Lammie PJ, Radday J, Beach MJ, Streit T, Wendt J, et al. Factors associated with participation in a campaign of mass treatment against lymphatic filariasis, in Leogane, Haiti. Ann Trop Med Parasitol 2004; 98: 703-14.
43. Raju K, Jambulingam P, Sabesan S, Vanamail P. Lymphatic filariasis in India: epidemiology and control measures. J Postgrad Med 2010; 56: 232-8.
44. Kumar P, Prajapati P, Saxena D, Kavishwar AB, Kurian G. An evaluation of coverage and compliance of mass drug administration 2006 for elimination of lymphatic filariasis in endemic areas of Gujarat. Indian J Commun Med 2008; 33: 38-42.
45. Taylor MJ, Bandi C, Hoerauf AM, Lazdins J. Wolbachia bacteria of filarial nematodes: a target for control? Parasitol Today 2000; 16: 179-80.
46. Darton-Hill I, Nalubola R. Fortification strategy to meet micronutrient needs: successes and failures. Proc Nutr Sci 2002; 61: 231-41.
47. Meyrowitsch DW, Simonsen PE, Magnussen P. Tolerance to diethylcarbamazine-medicated salt in individuals infected with Onchocerca volvulus. Trans R Soc Trop Med Hyg 2000; 94: 444-8.
48. Sudomo M, Chayabejara S, Duong S, Hernandez L, Wu WP, Bergquist R. Elimination of lymphatic filariasis in Southeast Asia. Adv Parasitol 2010; 72: 205-33.
49. Ramaiah KD. Lymphatic filariasis elimination programme in India: progress and challenges. Trends Parasitol 2009; 25: 7-8.
50. Mukhopadhyay AK, Patnaik SK, Satya Babu P, Rao KNMB. Knowledge on lymphatic filariasis and mass drug administration (MDA) programme in filaria endemic districts of Andhra Pradesh, India. J Vector Borne Dis 2008; 45: 73-5.
51. Bloom BS. Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews. Int J Technol Assess Health Care 2005; 21: 380-5.
52. Ramaiah KD, Das PK, Vanamail P, Pani SP. Impact of 10 years of diethylcarbamazine and ivermectin mass administration on infection and transmission of lymphatic filariasis. Trans R Soc Trop Med Hyg 2007; 101: 555-63.
53. Ichimori K, Graves PM, Crump A. Lymphatic filariasis elimination in the Pacific: PacELF replicating Japanese success. Trends Parasitol 2007; 23: 36-40.
54. Lahariya C, Pradhan SK. Can Southeast Asia eradicate yaws by 2010: some lessons from yaws eradication program in India. Natl Med J India 2007; 20: 81-6.
55. Lahariya C. Global eradication of polio: the case for finishing the job. Bull World Health Organ 2007; 85: 487-92.
56. Bockarie MJ, Pedersen EM, White GB, Michael E. Role of vector control in the global program to eliminate lymphatic filariasis. Ann Rev Entomol 2009; 54: 469-87.
57. Sunish IP, Rajendran R, Mani TR, Munirathinam A, Dash AP, Tyagi BK. Vector control complements mass drug administration against bancroftian filariasis in Tirukoilur, India. Bull World Health Organ 2007; 85: 138-45.